Department of Internal Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical College, Tokyo 162, Japan
|
|
- Gabriel Cooper
- 5 years ago
- Views:
Transcription
1 Endocrine Journal 1996, 43(6), Carboxy-Terminal Propeptide of Type 1 Procollagen (P1 CP) and Carboxy-Terminal Telopeptide of Type 1 Collagen (1 CTP) as Sensitive Markers of Bone Metabolism in Thyroid Disease MEGUMI MIYAKAWA, TosHlo TSUSHIMA, AND HIROSHI DEMURA Department of Internal Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical College, Tokyo 162, Japan Abstract. We measured serum levels of the carboxy-terminal propeptide of type 1 procollagen (P1CP) as a marker of bone formation and the carboxy-terminal telopeptide of type 1 collagen (1CTP) as a marker of bone resorption by RIA in sera from 40 Graves' disease patients and 14 Hashimoto's disease patients before and during treatment. The serum P1CP levels of the untreated Graves' disease were significantly higher than in the controls (176.8 ± 93.5 vs. 107 ± 35 ng/ml, P<0.01), and these levels decreased significantly during treatment with antithyroid drugs. There was a significant statistical correlation between serum P1CP levels and serum total alkaline-phosphatase activity (r=0.61, P<0.01) in the patients with Graves' disease and Hashimoto's disease as a whole. 1CTP levels were also significantly increased in untreated Graves' patients (6.5 ± 2.8 compared with 2.7 ± 1.1 ng/ml in normal subjects, P<0.01). The P1CP/1CTP ratio, which reflects the relative ratio of bone formation to bone resorption, was lower than normal in untreated Graves' disease, but increased following the normalization of thyroid function. The results of this study suggest that the measurement of serum P1CP and 1CTP levels may be useful in evaluating bone metabolism in thyroid disease. Key words: Carboxy-terminal propeptide of type 1 procollagen (P1CP), Carboxy-terminal telopeptide of type 1 collagen (1CTP), Graves' disease, Hashimoto's disease (Endocrine Journal 43: ,1996) TYPE 1 collagen is the most abundant collagen type in many soft tissues and accounts for over 90% of the organic matrix of bone [1, 2]. It is synthesized in the form of a larger protein, type 1 procollagen, which contains additional sequences at both ends [3]. These sequences are removed by specific proteinases before the collagen molecules are assembled into fibers [4]. The part removed from the carboxy-terminal end of the molecule, known as the carboxy-terminal propeptide of type 1 procollagen (P1CP), is released into the circula- Received: April 24, 1996 Accepted: August 6, 1996 Correspondence to: Dr. Megumi MIYAKAWA, Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical College, 8-1 Kawada-cho, Tokyo 162, Japan tion, and serum P1CP levels have been shown to provide a useful indicator of type 1 collagen synthesis, and consequently of bone formation [5]. On the other hand, the 1CTP (pyridinoline cross-linked telopeptide domain of type 1 collagen) is released in the process resolving of collagen fiber. Since 1CTP is not resolved any further, it has been proposed as a good marker of bone resorption [6]. Both serum P1CP and 1CTP concentrations have been determined in a variety of physiological states [7, 8] and disorders associated with altered bone metabolism [7-11]. Increased serum levels of P1CP and 1CTP have been reported in hyperthyroid patients with increased bone loss, suggesting increases in both bone formation and bone resorption [12-14], but there are few data on the simultaneous determination of serum P1CP and 1CTP in the same patients with thyroid disorders before and during
2 702 MIYAKAWA et al. treatment. In the present study, we measured the serum P1CP and 1CTP levels of patients with Graves' disease and Hashimoto's disease before and after treatment, and investigated correlation with thyroid function and other markers of bone metabolism. ulin antibody (TGHA). Six of the 14 patients with Hashimoto's disease were also tested for serum P1CP and 1CTP levels before and after treatment with thyroid hormone (Thyradin S; 50 to 100 µg / day). The mean duration of treatment was 6.2 ± 1.3 months. None of these patients had liver or renal dysfunction. The thyroid function data for all groups are summarized in Table 1. Patients Patients and Methods Forty patients with untreated Graves' disease (7 men and 33 women; mean age: 42.3 yr, range: years) and fourteen hypothyroid patients with Hashimoto's disease (all women; mean age: 42.9 yr, range: years) were included in this study. These patients were all pre-menopausal women because bone metabolism is different from that in post-menopausal women. Age-matched normal subjects (20 females and 10 males; mean age: 41.6 years) served as controls. Graves' disease was diagnosed on the basis of the clinical findings, high serum thyroid hormone (T4 and T3) levels with suppressed TSH levels, and positive TRAb (TSH-receptor antibody). Sixteen of the 40 patients were tested for serum P1CP and 1CTP levels before and after treatment with methimazole for 6 months when they became euthyroid, and another twenty-five patients with Graves' disease were also tested during treatment (20 females and 5 males; mean age: 43.6 years). The 14 patients with Hashirftoto's disease associated with hypothyroidism were diagnosed on the basis of subnormal serum thyroid hormone levels and high TSH levels (higher than 5,uU/ml), and high titer of microsomal antibody (MCHA) and/or thyroglob- Methods Serum concentrations of P1CP and 1CTP were determined with commercially available radioimmunoassay kits (P1CP and 1CTP RIA kit, Farmos Diagnostica, Oulunsalo, Finland). The intra- and interassay coefficients of variation were both below 5%, and the detection limit was 6 ng/ml for P1CP and 0.25 ng/ml for 1CTP. The source of the antigen was type 1 procollagen precipitated from the medium of cultured human skin fibroblasts [5]. Serum T3 and T4 were measured with commercial radioimmunoassay kits (Eiken Corp., Tokyo, Japan and Johnson & Johnson Clinical Diagnostics Ltd., Amersham, England, respectively). Serum TSH concentrations were measured by a sensitive immunoradiometric method (CIS Bio International, France). Serum TSH receptor antibody (TRAb) was measured with a kit (Johnson & Johnson Clinical Diagnostics Ltd., Amersham, England). Serum total alkaline-phosphatase was measured with a multichannel analyzer. All results are expressed as means ± SD. Statistical analysis was performed by using Wilcoxon non-parametric tests for paired and unpaired data, as indicated. Relationships between variables were tested by using Spearman's rank correlation test. P values <0.05 were considered significant. Table 1. Thyroid function data for thyroid disease patients
3 SERUM P1CP AND 1CTP LEVELS IN THYROID DISEASE 703 Fig. 2. Serum P1CP levels in patients with Graves' disease and Hashimoto's d isease before and after treatment. Fig.1. Serum P1CP levels in thyroid disease., untreated Graves' disease (n=40); A, treated Graves' disease with euthyroid state (n=25); 0, hypothyroid Hashimoto's disease (n=14). The shaded area indicates the normal range. Results Figure 1 shows serum P1CP concentrations patients with untreated and treated euthyroid Graves' disease and in Hashimoto's disease patients with hypothyroidism. P1CP levels in age-matched normal subjects were 107 ± 35 ng/ml. As shown in the figure, the mean serum concentration in the patients with untreated Graves' disease (176.8 ± 93.5 ng/ml) was significantly (P<0.01) higher than in normal subjects, although the values in two thirds of the patients were in the normal range. The values in treated Graves' disease patients who became euthyroidism (95.2 ± 30.8 ng/ml) were significantly (P<0.01) reduced and not different from normal values. The serum P1CP levels (99.3 ± 33.7 ng/ml) of the hypothyroid Hashimoto's disease patients were in the normal range except in one case. The serum P1CP concentrations of the 16 Graves' disease patients before treatment and after 6 in months of treatment with methimazole were compared (Fig. 2 left). The P1CP levels of every patient were 20-30% lower after they became euthyroid. The P1CP value after treatment was 89.3 ± 33.5 ng/ml, and significantly (P<0.005) lower than before treatment. Serum P1CP levels were also determined before and after treatment in patients with Hashimoto's disease. As shown in Fig. 2 (right), serum P1CP levels increased significantly, from ± 37.6 ng/ml to ± 70.6 ng/ml, in all patients after treatment. As shown in Fig. 3, P1CP levels were positively correlated with serum Al-P when both Graves' disease and Hashimoto's disease patients were included (r=0.61, P<0.001). There was also a positive correlation between these two variables in the Graves' disease patients alone, but there were no correlation between serum P1CP and thyroid hormones (Fig. 4), TRAb or serum Ca levels in any of the patients. Serum 1CTP levels were also high in the majority of untreated Graves' disease patients (Fig. 5). The mean value was 6.5 ± 2.8 ng/ml, and significantly (P<0.001) higher than normal (2.7 ± 1.1ng/ ml). The 1CTP level in hypothyroid Hashimoto's disease was 2.0 ± 1.0 ng/ml, which was not different from the value in normal subjects. The differences between serum 1CTP levels before and after treatment were examined in sixteen patients with Graves' disease and six patients with Hashimoto's disease (Fig. 6). As with P1CP levels, 1CTP levels decreased in all patients with Graves'
4 704 MIYAKAWA et al. Fig. 3. The relationship between serum total alkalinephosphatase activity and P1CP levels in patients with Graves' ( ) and Hashimoto's disease (0). The regression coefficient was 0.61(P<0.001). Fig. 5. Serum 1CTP levels in thyroid disease., untreated Graves' disease (n=40); ~, treated Graves' disease with euthyroid state (n=25); 0, hypothyroid Hashimoto's disease (n=14). The shaded area indicates the normal range. Fig. 6. Serum 1CTP levels in patients with Graves' disease and Hashimoto's disease before and after treatment. Fig. 4. The relationship between serum thyroid hormones (T3 or T4) and P1CP levels in patients with untreated Graves' disease (S) and Hashimoto's disease (0). disease after treatment (2.7 ± 1.0 ng/ml, P<0.005). Serum 1CTP levels in Hashimoto's disease were within the normal range both before and after treatment. As shown in Fig. 7, there were positive correlations between serum 1CTP and both T3 and T4 levels in the patients with Graves' disease and
5 SERUM P1CP AND 1CTP LEVELS IN THYROID DISEASE 705 Fig. 7. Relationship between serum T3 or T4 and 1CTP levels in patients with untreated Graves' disease ( ) and Hashimoto's disease (0). Hashimoto's disease (r=0.72, P<0.01 and r=0.64, P<0.01, respectively). Since serum T3 and T4 levels were not correlated with P1CP levels, 1CTP appears to be more sensitive to thyroid hormones. Bone turnover is regulated by both bone formation and bone resorption. We therefore calculated the serum P1CP/1CTP ratio in patients with Graves' disease during treatment (Fig. 8). The mean P1CP/1CTP value in untreated Graves' disease was 25.1 ± 24.0, and it increased to 37.8 ± 21.5 after 6 months of treatment with antithyroid drugs. The difference was significant (P<0.05), but the ratio was still lower than the control levels (73.4 ± 25.9). Although both bone formation and bone resorption were accelerated in hyperthyroidism, as evidenced by the increase in P1PC and 1CTP, the lower P1CP/1CTP ratio in the hyperthyroid state suggests that bone resorption predominates over bone formation. Discussion The data presented here demonstrate significantly increased serum concentrations of P1CP and 1CTP in patients with untreated Graves' disease, which was in agreement with earlier reports [8, 12-14]. We also showed that high P1CP levels returned to the normal range after 6 months of treatment with anti-thyroid drugs. Serum P1CP levels have been shown to be correlated with the Fig. 8. The ratio of serum P1CP to 1CTP in patients with Graves' disease before and after treatment. The shaded area indicates the normal range in control subjects (73.4 ± 25.9). iliac bone formation rate assessed histomorphometrically [15], with the mineral apposition rate, and with the bone formation rate [16]. Charles et al. [17], on the other hand, reported that serum P1CP levels were not different from those of normal subjects, in spite of increased skeletal mineralization and increased of serum concentrations of osteocalcin (OC), a marker of bone formation, and there was no correlation between serum Al-P activity and P1CP levels in their study. Their data conflict with the highly significant positive correlation between serum P1CP and Al-P in our study (regression coefficient; 0.61, P<0.001). This discrepancy may be due to differences between thyroid function, duration of hyperthyroidism, or menstrual state in the two groups, because, for example, Franklyn et al. (1994) reported a difference between the response to thyrotoxicosis to the skeletons of pre- and post-menopausal women, and a previous history of thyrotoxicosis rather than exogenous thyroxine therapy is a risk factor for bone loss in post-menopausal women [18].
6 706 MIYAKAWA et al. Serum P1CP levels have never been reported in hypothyroid patients before. The values in hypothyroid patients were similar to normal values in our study, but increased within the normal range in all patients after treatment with thyroxine, indicating that hypothyroidism decreases serum P1CP in individual patients. Several reports have correlated serum P1CP levels with other markers of bone formation in metabolic bone diseases. A positive correlation was reported between serum P1CP and OC levels in hyperthyroid patients [12]. Charles et al. [17] reported that OC is a reliable marker of mineralization, whereas Al-P and P1CP displayed disease-specific differences with respect to bone mineralization. They suggesed that P1CP reflects matrix formation alone, but a fraction of newly synthesized osteocalcin is incorporated into bone again, and the circulating serum osteocalcin is cleared by the kidneys, and thus its clearance is affected by renal function [19]. In contrast, P1CP is too large to be filtered by the renal glomeruli, and is removed from the blood by an endothelial receptor mechanism [20]. Since P1CP is produced in a constant molar ratio to type I collagen and is probably not incorporated into bone again, serum P1CP may be a better marker of bone formation than serum OC. We demonstrated a positive correlation between serum Al-P and P1CP in patients with thyroid diseases, including both Graves' disease and hypothyroid Hashimoto's disease. A positive correlation between Al-P and P1CP in thyroid diseases suggests that both bone mineralization and matrix formation are closely coupled. A number of markers for bone resorption have been developed. Urinary excretion of pyridinoline and deoxypyridinoline, in particular, have been shown to be useful markers of bone resorption. Increased excretion of these markers has been reported in patients with breast cancer, tumor-associated hypercalcemia [21, 22], and hyperthyroidism [23], but these markers include the cross-linked peptides not only of type I but type II collagen. On the other hand, 1CTP is the pyridinoline cross-linked telopeptide of type I collagen, and is more specific for bone resorption of type I collagen. Serum 1CTP levels have recently been shown to be increased in association with localized bone destruction in multiple myeloma [24] and osteolytic bone metastases. Our results showing that serum 1CTP levels were increased in the hyperthyroid Graves' disease patients are compatible with previous observations [14, 25, 26]. A positive correlation between serum 1CTP and thyroid hormone and the significant reduction in 1CTP levels after treatment suggests that serum 1CTP levels reflect a peripheral action of thyroid hormones on bone. Thus, both serum P1CP and 1CTP levels were increased in hyperthyroidism, suggesting that bone resorption and bone formation were accelerated, but serum P1CP/1CTP ratio, which reflects the relative rate of bone resorption and formation, was lower in the hyperthyroid state rather than the euthyroid state, indicating that bone resorption is more accelerated than bone formation in hyperthyroidism. It has been suggested that normalization of bone formation takes longer than that of resorption, according to the coupling theory [27]. Hyperthyroidism has been recognized as a risk factor for osteoporosis [18, 28]. In fact, histological studies have shown that thyroxine stimulates both osteoblast and osteoclast activity in cortical and trabecular bone, with resorptive surfaces exceeding formative surfaces, resulting in net bone loss [29, 30]. This was supported by a report by Rosen et al. [31] stating that total bone mass measured by DEXA decreased in thyrotoxic patients, and returned to normal after nine months of treatment. Our results are compatible with these previous observations. In summary, we have confirmed and extended previous findings showing that both bone resorption and formation, predominantly the former, are accelerated in hyperthyroid patients. RIAs for these markers provide useful information not only on bone metabolism, but on the effectiveness of antithyroid drug therapy. Acknowledgments We are indebted to Chugai Parmaceutical Co. for providing the P1CP and 1CTP kits. A part of the work was supported by the grant from Foundation of Growth Science.
7 SERUM P1CP AND 1CTP LEVELS IN THYROID DISEASE 707 References 1. Triffitt JT (1987) The special proteins of the bone tissue. Clin Sci 72: Burgeson RE (1988) New collagen, new concepts (Review). Annu Rev Cell Biol 4: Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA (1979) The bio-synthesis of collagen and its disorders (Review). N Engl J Med 301: Miyahara M, Njieha FK, Prockop DJ (1982) Formation of collagen fibrils in vitro by cleavage of procollagen with procollagen proteinases. J Biol Chem 257: Melkko J, Niemi S, Risteli L, Risteli J (1990) Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: Risteli J, Elomma I, Niemi S, Novamo A, Risteli L (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 39: Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CG, Mowat AP (1991) Serum concentration of the type I and III procollagen propeptide as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res 30: Saggese G, Bertelloni S, Baroncelli GI, Di Nero G (1992) Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 151: Taubman MB, Kammerman S, Goldberg B (1976) Radioimmunoassay of procollagen in serum of patients with Paget's disease of bone. Proc Soc Exp Biol Med 152: Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL (1984) Serum levels of Type I and II procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab 58: Carey DE, Goldberg B, Ratzan SK, Rubin KR, Rowe DW (1985) Radioimmunoassay for Type I procollagen in growth hormone-deficient children before and during treatment with growth hormone. Pediatr Res 19: Legovini P, De Menis E, Da Rin G, Roiter I, Breda F, Artuso V, Di Virgilio R, Conte N (1994) Increased serum levels of carboxyterminal propeptide of type I collagen (P1CP) in hyperthyroidism. Horm Metab Res 26: Ebeling PR, Peterson JM, Riggs BL (1992) Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 7: Wenisch C, Bank! HC, Schonthal E, Myskiw D, Presterl E, Rumpold H, Graninger W (1995) Serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter. Clin Immunol Immunopatho 75: Parfitt AM, Simon LS, Villanueva AR, Krane SM (1987) Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 2: Eliksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J (1993) Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry. J Bone Miner Res 8: Charles P, Hasling C, Risteli J, Mosekilde L, Eriksen EF (1992) Assessment of bone formation by biocheminal markers in metabolic bone disease: Separation between osteoblastic activity at the cell and tissue level. Calci f Tissue Int. 51: Franklyn J, Betteridge J, Holder R, Daykin J, Paterson CR, Sheppard M (1994) Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrino141: Delmas PD, Wilson DM, Mann KG, Riggs BL (1983) Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 57: Smedsrod B, Melkko J, Resteli L, Resteli J (1990) Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271: Paterson CR, Robins SP, Horobin JM, Preece PE, Cuschieri A (1991) Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 64: Body JJ, Delmas PD (1992) Urinary pyridium crosslinks as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74: Harvey RD, McHardy KC, Reid IW, Paterson F, Bewsher PD, Duncan A, Robins SP (1991) Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 72: Elomaa I, Virkkunen P, Risteli L, Risteli J (1992) Serum concentration of the cross-linked
8 708 MIYAKAWA et al. carboxyterminal telopeptide of type I collagen (1CTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66: Conti A, Monzani M, Persani L, Sartorio A (1994) Serum carboxyterminal cross-linked telopeptide of type I collagen in patients with thyroid disorders. Minerva Endocrinol 19: Persani L, Giammona E, Cortelazzi D, Beck-Peccoz P (1995) Carboxyterminal cross-linked telopeptide of type I collagen (1CTP) as an index of thyroid hormone effects on the bone. The 77th American Endocrine Meeting, Washington, DC. abstract P Martin TJ, Wah Ng K, Suda T (1989) Bone cell physiology. Endocrin Metab Clin N Am 18: Grant DJ, McMurdo MET, Mole PA, Paterson CR (1995) Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol 43: Allain TJ, McGregor AM (1993) Thyroid hormones and bone. J Endocrinol 139: Mosekilde L, Melsen F, Bagger JP, Myhere-H Jensen 0, Sorensen NS (1977) Bone changes in hyperthyroidism. Interrelationship between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol 85: Rosen CJ, Adler RA (1992) Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 75:
The effect of thyroid hormone on bone metabolism and osteoporosis. Creative Commons: Attribution 3.0 Hong Kong License
Title The effect of thyroid hormone on bone metabolism and osteoporosis Author(s) Kung, AWC Citation Journal Of The Hong Kong Medical Association, 1994, v. 46 n. 3, p. 247-251 Issued Date 1994 URL http://hdl.handle.net/10722/45079
More information(ICTP) I C (ICTP) 1) (NTx) 2,3) C (PICP) 4) Quality of Life (QOL) MRI ICTP ICTP II. ICTP. ICTP (Ccr) ICTP 22.6Log e (Ccr) (r 0.
485 I C (ICTP) * * * * * 126 I C (ICTP) 2 ICTP 1) ICTP (Ccr) ICTP 22.6Log e (Ccr) 111.4 (r 0.63, p 0.01) ICTP 2) Ccr 40 ml/min/1.73 m 2 ICTP 3) ICTP ICTP ICTP ( 39: 485 491, 2002) I. Quality of Life (QOL)
More informationHealthy Infants and Children. 442 healthy white Caucasian subjects between 3 wk and 18 y of age were studied (2 15 females,
003 1-3998/91/3003-0276$03.00/0 PEDIATRIC RESEARCH Copyright O 199 1 International Pediatric Research Foundation, Inc. Val. 30, No. 3, 1991 Printed in U.S.A. Serum Concentrations of the Type I and I11
More informationDecreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing s syndrome
European Journal of Endocrinology (1999) 141 126 131 ISSN 0804-4643 CLINICAL STUDY Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationUniversity of Medicine and Pharmacy Craiova. Faculty of Medicine. PhD THESIS ABSTRACT
University of Medicine and Pharmacy Craiova Faculty of Medicine PhD THESIS ABSTRACT STUDY OF THE CHANGES IN BONE MASS AND BONE METABOLISM MARKERS IN THYROTOXIC OSTEOPOROSIS. THERAPEUTIC IMPLICATIONS. Scientific
More informationUsefulness of bone metabolic markers in the diagnosis
British Joumal of Cancer (997) 76(6), 760-764 997 Cancer Research Campaign Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer A Arugal, M Koizumi2,
More information* 2 Third Department of Internal Medicine, Kyorin University School of Medicine
Diabetes Mellitus and Metabolic Bone Disorder Kiyoshi Suzuki * 1, Makoto Takizawa * 2, Eij i Itagaki * 2 and Hitoshi Ishida * 2 * 1 Shimada Municipal Hospital ; * 2 Third Department of Internal Medicine,
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationSERUM CALCIUM AND PHOSPHOROUS LEVELS IN THYROID DYSFUNCTION
SERUM CALCIUM AND PHOSPHOROUS LEVELS IN THYROID DYSFUNCTION *Shivaleela MB, Poornima RT and Jayaprakash Murthy DS Department of Biochemistry, J. J. M. Medical College, Davangere -577004, Karnataka, India.
More informationCollagen Crosslinks, Any Method
190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement
More information"Role of thyroid hormones in bone development and maintenance"
"Role of thyroid hormones in bone development and maintenance" Graham R. Williams Molecular Endocrinology Group Department of Medicine & MRC Clinical Sciences Centre Imperial College London Thyroid hormones
More informationClinical significance of metabolic superscan in patients with hyperthyroidism
Original Nuclear Medicine Review 2007 Vol. 10, No. 2, pp. 76 81 Copyright 2007 Via Medica ISSN 1506 9680 Clinical significance of metabolic superscan in patients with hyperthyroidism Magdy H. Kotb 1, Tarek
More informationEffects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric
More informationRelationship between bone resorption and adrenal sex steroids and their derivatives in oophorectomized women
FERTILITY AND STERILITY VOL. 82, NO. 6, DECEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Relationship between bone
More informationCollagen Crosslinks, Any Method
190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement
More informationINCREASED NEED FOR THYROXINE IN WOMEN WITH HYPOTHYROIDISM DURING ESTROGEN THERAPY
INCREASED NEED FOR THYROXINE IN WOMEN WITH HYPOTHYROIDISM DURING ESTROGEN THERAPY BAHA M. ARAFAH, M.D. ABSTRACT Background Women with hypothyroidism that is being treated with thyroxine often need higher
More informationKey words: Collagen synthesis - N-Terminal peptide of type III procollagen - Tumor marker - Liver cancer - Liver cirrhosis
[Gann, 75, 130-135; February, 1984] HIGH CONCENTRATIONS OF N-TERMINAL PEPTIDE OF TYPE III PROCOLLAGEN IN THE SERA OF PATIENTS WITH VARIOUS CANCERS, WITH SPECIAL REFERENCE TO LIVER CANCER Terumasa HATAHARA,
More informationORIGINAL ARTICLE SERUM OSTEOCALCIN, SHALL WE CONSIDER IT AS A BIOCHEMICAL MARKER FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
SERUM OSTEOCALCIN, SHALL WE CONSIDER IT AS A BIOCHEMICAL MARKER FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN V. S. Kalai Selvi 1, K. Prabhu 2, Monika Gupta 3. HOW TO CITE THIS ARTICLE: V. S. Kalai Selvi, K.
More informationTSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves disease and Graves orbitopathy
original article TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves disease and Graves orbitopathy Mira Siderova 1, Kiril Hristozov 1, Aleksandra Tsukeva 2 ABSTRACT
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationThyroid Disease in Pregnancy. Justin Moore, MD
Thyroid Disease in Pregnancy Justin Moore, MD Case 1 22 yr old G1P0 female at 14 2/7 weeks presents with tremor Weight stable since first positive pregnancy test Some nausea, rare vomiting TSH 0.02 miu/l,
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationChanges in the Tumor Marker Concentration in Female Patients with Hyper-, Eu-, and Hypothyroidism
Endocrinol. Japon. 1989, 36 (6), 873-879 Changes in the Tumor Marker Concentration in Female Patients with Hyper-, Eu-, and Hypothyroidism TAKUMA HASHIMOTO AND FUJITSUGU MATSUBARA Department of Laboratory
More information25/10/56. Hypothyroidism Myxedema in adults Cretinism congenital deficiency of thyroid hormone Hashimoto thyroiditis. Simple goiter (nontoxic goiter)
THERAPEUTIC USES OF THYROID HORMONE Supeecha Wittayalertpunya Wannarasmi Ketchart Nov 2013 Hyperthyroidism (Thyrotoxicosis) Grave s disease (diffuse toxic goiter) Toxic uninodular & Toxic multinodular
More informationA Case of Total Thyroxine-Binding Globulin Deficiency with Graves1 Disease: Fluctuations of Plasma Triiodothyronine/Thyroxine Ratio
Case Report A Case of Total Thyroxine-Binding Globulin Deficiency with Graves1 Disease: Fluctuations of Plasma Triiodothyronine/Thyroxine Ratio Keita Kamikubo, Noriko Kojima, Noriyoshi Yamakita and Kiyoshi
More informationGalactorrhea in Subclinical Hypothyroidism. Division of Endocrinology and Metabolism,
Endocrinol. Japon. 1987, 34 (4), 539-544 Galactorrhea in Subclinical Hypothyroidism TAKAJI TAKAI, KUNIHIRO YAMAMOTO, KOSHI SAITO, KAZUKO ANDO, TOSHIKAZU SAITO AND TAKESHI KUZUYA Division of Endocrinology
More informationINTRODUCTION. Original Article
J Bone Metab 2015;22:135-141 http://dx.doi.org/10.11005/jbm.2015.22.3.135 pissn 2287-6375 eissn 2287-7029 Original Article Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients
More informationEffectiveness Of Fixed Dose Radioactive Iodine (Rai) For The Treatment Of Thyrotoxicosis : A United Kingdom District General Hospital Experience
ISPUB.COM The Internet Journal of Endocrinology Volume 5 Number 2 Effectiveness Of Fixed Dose Radioactive Iodine (Rai) For The Treatment Of Thyrotoxicosis : A United Kingdom District General Hospital Experience
More informationAcute fasting diminishes the circadian rhythm of biochemical markers of bone resorption
European Journal of Endocrinology (1999) 140 332 337 ISSN 0804-4643 Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption A Schlemmer and C Hassager Center for Clinical
More informationTOMOFUSA USUI M.D.* information has been available on zinc status in. thyroid disease. The present study was undertaken
Postgraduate Medical Journal (December 198) 56, 833-837 YOSHIKAZU NISHI M.D.* Zinc metabolism in thyroid disease TOMOFUSA USUI M.D.* RYOSO KAWATE M.D.t *Department of Pediatrics, and tdepartment of Internal
More informationLABORATORY TESTS FOR EVALUATION OF THYROID DISORDERS
LABORATORY TESTS FOR EVALUATION OF THYROID DISORDERS Maryam Tohidi Anatomical & clinical pathologist Research Institute for Endocrine Sciences THYROID GLAND (15-25 gr), (12-20 gr), 2 lobes connected by
More informationMonitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women
727 REVIEW Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women E Dogan, C Posaci... Biochemical markers of bone metabolism are divided into two groups:
More informationSerum Thyroglobulin (Tg) Concentration in Healthy Subjects Absence of Age- and Sex-related Differences
Endocrinol. Japon. 1984, 31 (1), 93-98 NOTE Serum Thyroglobulin (Tg) Concentration in Healthy Subjects Absence of Age- and Sex-related Differences SHIGENORI NAKAMURA, SHIGEKI SAKATA, YOSHIAKI MINAMORI,
More informationClinical Evaluation of the Elecsys -CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides
Clinical Chemistry 47:8 1410 1414 (2001) Enzymes and Protein Markers Clinical Evaluation of the Elecsys -CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides Reiko
More informationMeasurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases
British Journal of Cancer (1999) 8(8), 1265 127 Article no. bjoc.1999.496 Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases J Walls
More informationMASATERU HORIMOTO, MITSUSHIGE NISHIKAWA, CHISATO UNO, NoRIO YOSHIKAWA, NORIMICHI TANIGUCHI AND MITSUO INADA
Relationship among Thyrotropin (TSH), Thyroid Stimulating Immunoglobulins, and Results of Triiodothyronine (T3) Suppression Test in Patients with Graves' Disease MASATERU HORIMOTO, MITSUSHIGE NISHIKAWA,
More informationBiochemistry #02. The biochemical basis of skeletal muscle and bone disorders Dr. Nabil Bashir Bara Sami. 0 P a g e
]Type text[ ]Type text[ ]Type text[ Biochemistry #02 The biochemical basis of skeletal muscle and bone disorders Dr. Nabil Bashir Bara Sami 0 P a g e Greetings everyone, ladies and gentlemen The biochemical
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationproduction in healthy man Introduction
Journal of Internal Medicine 1997; 241: 143 150 Effects of short-term insulin-like growth factor-i or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1,25 dihydroxyvitamin production
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationResearch Article Study of Serum Calcium, Magnesium And Phosphorous Levels In Patients With Thyroid Disorders
Research Article Study of Serum Calcium, Magnesium And Phosphorous Levels In Patients With Thyroid Disorders Dr. Shweta R. Hebbar*, Dr. Nagarajappa. K., Dr. Sushma B. J, Dr. C. R. Mallikarjun Department
More informationBone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover. Original Policy Date
MP 2.04.10 Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013
More informationBiochemistry #01 Bone Formation Dr. Nabil Bashir Farah Banyhany
Biochemistry #01 Bone Formation Dr. Nabil Bashir Farah Banyhany Greetings This lecture is quite detailed, but I promise you will make it through, it just requires your 100% FOCUS! Let s begin. Today s
More informationRapid Inhibition of Thyroxine-Induced Bone Resorption in the Rat by an Orally Active Vitronectin Receptor Antagonist
0022-3565/02/3021-205 211$7.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 302, No. 1 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 4639/990532
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationOsteoporosis Alternatives. James Biddle, MD
Disclaimer This is simply an educational presentation and is not intended to diagnose or treat any individuals. Diagnosis and treatment of any disease should be done by a licensed healthcare practitioner
More informationNon-specific Activities against Ruthenium Crosslinker as a New Cause of Assay Interference in an Electrochemilluminescent
CASE REPORT Non-specific Activities against Ruthenium Crosslinker as a New Cause of Assay Interference in an Electrochemilluminescent Immunoassay Takao Ando 1, Jun-ichi Yasui 1, Naoko Inokuchi 2, Toshiro
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationReceived 1 March 2002; accepted for publication 28 July 2002
British Journal of Haematology, 2003, 120, 235 242 Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early
More informationBone strength is proportional to bone mass, measured with DXA. Bone turnover markers indicate the status of bone quality.
Bone strength is proportional to bone mass, measured with DXA Bone quality depend on bone architecture, rate of bone turnover, quality of bone matrix. Bone turnover markers indicate the status of bone
More informationThyroid in the elderly. Akbar Soltani M.D. Endocrinology and Metabolism Research Center (EMRC) Shariati Hospital
Thyroid in the elderly Akbar Soltani M.D. Endocrinology and Metabolism Research Center (EMRC) Shariati Hospital soltania@tuma.ac.ir Case 1 A 79 year old female is seen because of a 6 month history of fatigue,
More informationantiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients
British Journal of Cancer (1998) 78(2), 240245 1998 Cancer Research Campaign Aminoterminal propeptide of type procollagen (PNP) correlates to bone loss and predicts the efficacy of antiresorptive therapy
More informationGenetic examination of diseases affecting bone development. and structure in newborns
Genetic examination of diseases affecting bone development and structure in newborns Examination of molecular genetic markers in osteopenic preterm infants PhD Thesis Simone Funke, MD University of Pécs
More informationAnalysis of Lag Behind Thyrotropin State After Radioiodine Therapy in Hyperthyroid Patients
Analysis of Lag Behind Thyrotropin State After Radioiodine Therapy in Hyperthyroid Patients ORIGINAL ARTICLE Mohshi Um Mokaddema, Fatima Begum, Simoon Salekin, Tanzina Naushin, Sharmin Quddus, Nabeel Fahmi
More informationPrognostic Value of Serum Hyaluronic Acid and Type I and I11 Procollagen Propeptides in Extrahepatic Biliary Atresia
0031-3998/95/3804-056S$03.00/0 PEDIATRIC RESEARCH Copyright O 1995 International Pediatric Research Foundation, Inc. Vol. 38, No. 4, 1995 Printed in U.S.A. Prognostic Value of Serum Hyaluronic Acid and
More informationHYPOTHYROIDISM AND HYPERTHYROIDISM
HYPOTHYROIDISM AND HYPERTHYROIDISM SHAHIDA PERVEEN, AMBREEN Post RN BSCN Semester II FACULTY SIR RAJA April 13, 016 Objectives: State the functions of thyroid hormone. Understand the pathologic mechanism
More informationProgram Outline / page 1. I. Get Acquainted With Your Hormone System. III. Learn Why The Thyroid Gland is Important for Your Health
Program Outline / page 1 Module 1 I. Get Acquainted With Your Hormone System What is the endocrine system? What are hormonal rhythms? What are the main hormonal networks and axis? II. Know Your Thyroid
More informationPage: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover
Last Review Status/Date: December 2014 Page: 1 of 12 Management of Osteoporosis and Diseases Description Bone turnover markers are biochemical markers of either bone formation or bone resorption. Commercially
More informationANTITHYROID drugs are effective in controlling
220 THE NEW ENGLAND JOURNAL OF MEDICINE Jan. 25, 996 LACK OF EFFECT OF THYROXINE IN PATIENTS WITH GRAVES HYPERTHYROIDISM WHO ARE TREATED WITH AN ANTITHYROID DRUG BRYAN MCIVER, M.B., CH.B., PETER RAE, M.B.,
More informationWHAT KEEPS OUR BONES STRONG?
WHAT KEEPS OUR BONES STRONG? The role of diet and lifestyle in osteoporosis prevention Thomas Walczyk PhD, Associate Professor Food Science and Technology Programme Department of Chemistry, Faculty of
More informationBone mineral density in hypoparathyroid women on LT 4 suppressive therapy. Effect of calcium and 1,25(OH) 2 vitamin D 3 treatment
J Musculoskel Neuron Interact ; ():7-76 Original Article Hylonome Bone mineral density in hypoparathyroid women on LT suppressive therapy. Effect of calcium and,5(oh) vitamin D treatment F. Hawkins, F.
More informationLecture title. Name Family name Country
Lecture title Name Family name Country Nguyen Thy Khue, MD, PhD Department of Endocrinology HCMC University of Medicine and Pharmacy, MEDIC Clinic Hochiminh City, Viet Nam Provided no information regarding
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationChanges in Bone Mineral Density and Metabolism in Women: Evaluation of bodily characteristics, bone metabolic markers and bone mineral density
Hiroshima J. Med. Sci. Vol. 62, No. 3, 49~53, September, 2013 HIJM 62 9 49 Changes in Bone Mineral Density and Metabolism in Women: Evaluation of bodily characteristics, bone metabolic markers and bone
More informationThe major clinical features of multiple. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma
[haematologica] ;89:57-577 Multiple Myeloma Research Paper Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma NIELS ABILDGAARD KIM BRIXEN ERIK FINK
More informationImmunoassays. EIA & RIA Product Portfolio. Commitment to innovation
Immunoassays EIA & RIA Portfolio Commitment to innovation info@idsplc.com www.idsplc.com Expertise in Endocrinology Diagnostics Immunodiagnostic Systems Limited is a leading in vitro diagnostic solutions
More informationUsefulness of Bone Metabolic Markers in the Diagnosis of Bone Metastasis from Lung Cancer
Yonsei Medical Journal Vol. 46, No. 3, pp. 388-393, 2005 Usefulness of Bone Metabolic Markers in the Diagnosis of Bone Metastasis from Lung Cancer Jae Ho Chung 1, Moo Suk Park 2, Young Sam Kim 2,3, Joon
More informationJari Satta, MD, Tam Juvonen, MD, PhD, Kari Haukipuro, MD, PhD, Minna Juvonen, MD, PhD, and Matti I. Kairaluoma, MD, PhD, Oulu, Finland
ncreased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type procollagen in peripheral and aortal blood samples Jari
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationChanges of bone mineral density, quantitative ultrasound parameters and markers of bone turnover during treatment of hyperthyroidism
ORIGINAL ARTICLE Changes of bone mineral density, quantitative ultrasound parameters and markers of bone turnover during treatment of hyperthyroidism A.C. van de Ven *, R.J. Erdtsieck Department of Internal
More informationNone. Thyroid Potpourri for the Primary Care Physician. Evaluating Thyroid Function. Disclosures. Learning Objectives
Thyroid Potpourri for the Primary Care Physician Ramya Vedula DO, MPH, ECNU Endocrinology, Diabetes and Metabolism Princeton Medical Group Assistant Professor of Clinical Medicine Rutgers Robert Wood Johnson
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationChapter I.A.1: Thyroid Evaluation Laboratory Testing
Chapter I.A.1: Thyroid Evaluation Laboratory Testing Jennifer L. Poehls, MD and Rebecca S. Sippel, MD, FACS THYROID FUNCTION TESTS Overview Thyroid-stimulating hormone (TSH) is produced by the anterior
More informationTHE EFFECT OF DIETARY NUTRIENTS ON OSTEOCHONDROSIS IN SWINE AND EVALUATION OF SERUM BIOMARKERS TO PREDICT ITS OCCURRENCE. NOLAN ZEBULON FRANTZ
THE EFFECT OF DIETARY NUTRIENTS ON OSTEOCHONDROSIS IN SWINE AND EVALUATION OF SERUM BIOMARKERS TO PREDICT ITS OCCURRENCE. by NOLAN ZEBULON FRANTZ B.S., Tabor College, 2001 B.S., Kansas State University,
More informationThyroid, antithyroid, parathyroid & Calcium metabolism. Suharti K Suherman Dept. of Pharmacology & Therapeutic Medical Faculty, Univ.
Thyroid, antithyroid, parathyroid & Calcium metabolism Suharti K Suherman Dept. of Pharmacology & Therapeutic Medical Faculty, Univ. of Indonesia Thyroid secreted by thyroid gland source of 2 different
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationThe subjects were participants in a Dutch national prospective study, running from April
Supplemental Data Subjects The subjects were participants in a Dutch national prospective study, running from April 1, 1994 to April 1, 1996. Infants with neonatal screening results indicative of CH-C
More informationReview Article Metabolic and Clinical Consequences of Hyperthyroidism on Bone Density
International Journal of Endocrinology Volume 2013, Article ID 638727, 11 pages http://dx.doi.org/10.1155/2013/638727 Review Article Metabolic and Clinical Consequences of Hyperthyroidism on Bone Density
More informationPathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD
Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass
More informationUvA-DARE (Digital Academic Repository) Treatment of primary HIV infection Grijsen, M.L. Link to publication
UvA-DARE (Digital Academic Repository) Treatment of primary HIV infection Grijsen, M.L. Link to publication Citation for published version (APA): Grijsen, M. L. (2013). Treatment of primary HIV infection
More informationInternational Journal of Pure and Applied Sciences and Technology
Int. J. Pure Appl. Sci. Technol., 30(1) (2015), pp. 18-23 International Journal of Pure and Applied Sciences and Technology ISSN 2229-6107 Available online at www.ijopaasat.in Research Paper Thyroid Dysfunction
More informationsuffering from hyperthyroidism before and after treatment have shown variable J. Physiol. (1958) I42,
447 J. Physiol. (1958) I42, 447-452 BONE CALCIUM AND SODIUM CONTENT AND THE EXCHANGE OF RADIOSODIUM IN BONES FROM RATS TREATED WITH THYROXINE AND PARATHORMONE BY D. S. MUNRO, R. S. SATOSKAR AND G. M. WILSON
More informationSlide notes: This presentation provides information on Graves disease, a systemic autoimmune disease. Epidemiology, pathology, complications,
1 This presentation provides information on Graves disease, a systemic autoimmune disease. Epidemiology, pathology, complications, including ophthalmic complications, treatments (both permanent solutions
More informationA retrospective cohort study: do patients with graves disease need to be euthyroid prior to surgery?
Al Jassim et al. Journal of Otolaryngology - Head and Neck Surgery (2018) 47:37 https://doi.org/10.1186/s40463-018-0281-z ORIGINAL RESEARCH ARTICLE Open Access A retrospective cohort study: do patients
More informationAwaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page
f #3 Awaisheh Abdullah Alaraj Mousa Al-Abbadi 1 Page *This sheet was written from Section 1 s lecture, in the first 10 mins the Dr. repeated all the previous material relating to osteoporosis from the
More informationBiomarker Insights. Utility of C-terminal Telopeptide in Evaluating Levothyroxine Replacement Therapy-Induced Bone Loss
Open Access: Full open access to this and thousands of other papers at http://www.la-press.com. Biomarker Insights Utility of C-terminal Telopeptide in Evaluating Levothyroxine Replacement Therapy-Induced
More informationClinical, Endocrinological and Immunological Characteristics of Japanese Patients With Autoimmune Polyglandular Syndrome Type 3a
Elmer ress Original Article J Endocrinol Metab. 2016;6(2):46-51 Clinical, Endocrinological and Immunological Characteristics of Japanese Patients With Autoimmune Polyglandular Syndrome Type 3a Sumie Moriyama
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationRADIOIMMUNOASSAY OF THYROID RELATED HORMONES AND TSH IN PRIMARY HYPERTHYROIDISM
RADIOIMMUNOASSAY OF THYROID RELATED HORMONES AND TSH IN PRIMARY HYPERTHYROIDISM Pages with reference to book, From 215 To 219 Farida Agha ( Pakistan Medical Research Council, Research Centre, Karachi.
More informationDiagnostic Value of Urine Deoxypyridinoline for Detecting Bone Metastases in Breast Cancer Patients
Annals of Clinical & Laboratory Science, vol. 33, no. 1, 2003 55 Diagnostic Value of Urine Deoxypyridinoline for Detecting Bone Metastases in Breast Cancer Patients Ming-Feng Hou, 1 Shwu-Bin Lin, 2 Shyng-Shiou
More informationB-Resistance to the action of hormones, Hormone resistance characterized by receptor mediated, postreceptor.
Disorders of the endocrine system 38 Disorders of endocrine system mainly are caused by: A-Deficiency or an excess of a single hormone or several hormones: - deficiency :can be congenital or acquired.
More informationEndocrine system pathology
Endocrine system pathology Central endocrine system peripheral endocrine system: thyroid gland parathyroid gland pancreas adrenal glands Thyroid gland. the weight of normal thyroid gland is about 15 grams.
More informationand Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects
Serum Follicular - Stimulating Hormone and Luteinizing Hormone as Measured by Radioimmunoassay Correlated with Sexual Development in Hypopituitary Subjects ROBERT PENNY, THOMAS P. FOLEY, JR., and ROBERT
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 10, 2002 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationRegulation of the skeletal mass through the life span
Regulation of the skeletal mass through the life span Functions of the skeletal system Mechanical protection skull Movement leverage for muscles Mineral metabolism calcium store Erythropoiesis red blood
More informationA 12-Month Prospective Study of the Relationship Between Stress Fractures and Bone Turnover in Athletes
Calcif Tissue Int (1998) 63:80 85 1998 Springer-Verlag New York Inc. A 12-Month Prospective Study of the Relationship Between Stress Fractures and Bone Turnover in Athletes K. L. Bennell, 1 S. A. Malcolm,
More information